Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

NanoViricides plans to lease new cGMP manufacturing and lab space

NanoViricides, Inc. announced today that it will be leasing new space for cGMP production of its nanoviricides drug candidates against various viral diseases.

20 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

Mother and baby cytomegalovirus screening important to prevent consequences

According to health experts, pregnant women and newborns should be screened for a virus that causes brain damage and deafness. The study that appeared in the latest issue of The Medical Journal of Australia yesterday says hundreds of cases of cytomegalovirus (CMV) are likely being missed each year in Australia because of a lack of screening, denying babies treatment for the condition.

19 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Boosting immune response may cause cold-induced asthma flare-ups

People often talk about "boosting" their immunity to prevent and fight colds. Nutritional supplements, cold remedies and fortified foods claim to stave off colds by augmenting the immune system.

18 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

Structural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Public Health Grid technology could address specific surveillance needs for pandemic disease control

An evaluation of the Public Health Grid (PHGrid) technology during the 2009 H1N1 influenza pandemic could enhance the capabilities of epidemiologists and disease-control agencies when the next emergent disease appears, according to a study published in the International Journal of Grid and Utility Computing.

17 Jun 2011

Boosting immune response could increase inflammation

People often talk about "boosting" their immunity to prevent and fight colds. Nutritional supplements, cold remedies and fortified foods claim to stave off colds by augmenting the immune system.

16 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza

BiondVax Pharmaceuticals Ltd. today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

16 Jun 2011

Geisinger uses mandatory approach to improve healthcare worker influenza vaccination rates

Geisinger Health System vaccinated more than 92% of all employees against influenza this season, with a modification of a mandatory program. On average, fewer than half of all healthcare workers receive flu vaccinations.

16 Jun 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Inviragen announced today the initiation of the first clinical trial of the Company's proprietary Hand, Foot and Mouth Disease (HFMD) investigational vaccine, INV21, a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71.

16 Jun 2011

High proportion of men with prostate cancer die from the disease

Up to half the number of men with prostate cancer who die do so as a direct result of the disease, rather than from other causes according to a new study presented at the National Cancer Intelligence Network conference in London.

15 Jun 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

NanoViricides plans to lease new cGMP manufacturing and lab space

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Mother and baby cytomegalovirus screening important to prevent consequences

FDA approves NULOJIX

Boosting immune response may cause cold-induced asthma flare-ups

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effects

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Public Health Grid technology could address specific surveillance needs for pandemic disease control

Boosting immune response could increase inflammation

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza

Geisinger uses mandatory approach to improve healthcare worker influenza vaccination rates

Serious RSV infections may occur in previously healthy infants and children

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

High proportion of men with prostate cancer die from the disease

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Newsletters you may be interested in